A Boston-based investment group that provides funding to early-stage life science and healthcare companies. The Sky Ventures Group includes top-tier corporate venture capital, foundations, family offices and individual angel investors who want to change the early stage investment landscape and impact lives by building outstanding life science & healthcare companies.

Eyal Geffen


Co-Founder & Managing Partner

  • Grey LinkedIn Icon

Henry Kay


Investment Advisor

  • Grey LinkedIn Icon

Eyal Geffen has 17 years of demonstrated success in various management and hands on positions. He has had experience with large corporations, coupled with extensive background building and running new ventures and comprehensive knowledge of international markets. Sky Ventures Group was founded by Eyal Geffen and Dr. Raphael Nir in 2015. As a Managing Partner, Eyal is responsible for all management and day to day operations. Previously, he held a variety of leadership positions including;  Co-Founder at RANDG, VP Business Development & Sales at Med-1, Business Partner Manager at HP and VP Marketing & Business Development at ThinCom. Eyal has a BSc in Business Administration and an MBA. 




+1 617-678-9766

Henry Kay is an active angel investor. He retired from Boston Scientific in 2006, where he was Group Vice President of New Market Development / Strategic Planning, Endosurgery Boston Scientific Corporation (BSC). Prior to joining BSC, Henry was based in the UK for five years as Senior Vice President, Sales and Marketing for Allergan Europe, a global eye care company. He has 35 years of experience in the medical industry in roles which include R&D, International Marketing, Regulatory Affairs, and Strategic Planning for major pharmaceutical companies, including Schering-Plough, American Home Products, Sterling Drug and Allergan.


Henry is a fellow of the Royal Society of Medicine (UK).  He serves on the Boards of several start up health care companies, including Smart Cells (sold to Merck in 2010), Cool Systems, Avaxia, Christcot Medical, and Cannuflow.  He was a member of the board of Directors of Microfluidics, a public company in the equipment space for pharmaceutical manufacture (sold to IDEX in 2010).  Internationally, he serves on the boards of 3 Canadian Medical Device companies (Cellaegis Devices, MyndTec and Exact Imaging in Toronto. He is a mentor with the Venture Mentoring Service of MIT and works closely with the Canadian Consulate in Boston to mentor Canadian startups. He serves on the Board of Overseers of Beth Israel-Deaconess and Newton Wellesley Hospitals. In addition, he is serving on the boards of Neurofibromatosis (NF Inc.) and JF&CS, both nonprofit organizations. Henry holds Bachelors (Augusta College) and Master’s Degrees in Chemistry from Rutgers University, and an MBA in International Marketing from Seton Hall University. Henry is a past President of Temple Beth Elohim in Wellesley, Massachusetts.  Henry and his wife Laurie have one grown daughter and reside in Weston, Massachusetts.

Jon Leibowitz


Investment Advisor

  • Grey LinkedIn Icon

Kevin J. Scanlon


Investment Advisor

  • Grey LinkedIn Icon

Dr. Scanlon’s background includes: academic medicine, senior management in the pharmaceutical industry, CEO of four start up biotechnology companies and was the Chairman of Pasadena Angels Investment Group. He was recognized by LA Techweek as an individual who has significantly impacted the Los Angeles business and technology community. Previously worked with entrepreneurs and government leaders in Ireland, New Zealand and China. He has managed the genomic and cancer programs across the US, Europe and Asia for Berlex-Schering. He was named a Leukemia Society Scholar and Leukemia Society of America Fellow. Co-Founded and Co-Edited the Nature Journal “Cancer Gene Therapy” and he served as President of the International Society of Cell and Gene Therapy. He was awarded the Paul Martini Medical Research Prize for cancer research. Published author of 135 peer-reviewed scientific articles and nine medical books. Also holds seven US patents. Currently, he is the Professor of Practice at the D'Amore-McKim School of Business, Northeastern University. 

Jon Leibowitz is a business owner, investor and advisor with over 25 years experience working in high growth healthcare and business-to-business environments.  Jon is a member of the executive team at DBC Pri-Med, a leading medical information and education company serving primary care physicians. He also serves as a founder, partner or active advisor to a number of other healthcare companies including Pleio Inc., a leading medication adherence company; NEJM Group, whose products include the New England Journal of Medicine, NEJM Journal Watch and NEJM Knowledge+; WikiDoc, the world’s largest open source medical encyclopedia; and Lighthouse Learning, a healthcare information and education content company serving physicians and patients. 


Jon has worked as CEO for Lighthouse Learning; as an Executive Vice President for Questex Media; as a founding partner and Managing Director for M|C Communications, a company that he and his fellow partners later sold to Bain Capital; as a Vice President for Fidelity Capital Companies, as a Group Vice President for Reed-Elsevier, and as a healthcare management consultant for APM. 


Jon is also a member of the Beth Israel Deaconess Board of Advisors, currently serving on its finance committee.  Jon has a BA from Hamilton College and an MBA from The Wharton School of Business.




  • LinkedIn Reflection
  • Twitter Classic



Investing in a Healthier Future